Anzeige
Mehr »
Login
Dienstag, 07.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Warum der Warren Buffett des Bergbaus alles auf diese Aktie setzt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QNWR | ISIN: US8808811074 | Ticker-Symbol: 430
Tradegate
06.01.25
15:31 Uhr
5,600 Euro
+0,050
+0,90 %
1-Jahres-Chart
TERNS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
TERNS PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
5,4505,55006.01.
5,4505,55006.01.

Aktuelle News zur TERNS PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)34FOSTER CITY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule...
► Artikel lesen
03.12.24Terns reports positive early results in CML drug trial5
03.12.24Terns meldet positive erste Ergebnisse in CML-Medikamentenstudie7
03.12.24Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia96Compelling molecular responses starting at lowest dose level in heavily pre-treated patients with high baseline BCR-ABL transcript levels Encouraging safety profile with no dose limiting toxicities...
► Artikel lesen
TERNS PHARMACEUTICALS Aktie jetzt für 0€ handeln
03.12.24Terns Pharmaceuticals, Inc. - 8-K, Current Report-
02.12.24Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)50FOSTER CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule...
► Artikel lesen
18.11.24Terns Pharmaceuticals appoints new board member3
18.11.24Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors1
18.11.24Terns Pharmaceuticals, Inc. - 8-K, Current Report-
12.11.24Terns Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
31.10.24Oppenheimer stuft Terns Pharmaceuticals mit "Outperform" ein und sieht 150% Aufwärtspotenzial14
31.10.24Oppenheimer initiates Terns Pharmaceuticals stock at Outperform, sees 150% upside1
07.10.24Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)104FOSTER CITY, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule...
► Artikel lesen
30.09.24Terns Pharmaceuticals stock target lifted on obesity drug data21
20.09.24Viking, Structure, Terns benefitting from disappointing Novo Nordisk weight loss data15
18.09.24Terns Pharmaceuticals director buys $5 million in company stock5
13.09.24Terns Pharmaceuticals, Inc.: Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares3
13.09.24Terns Pharmaceuticals CFO sells $110,000 in company stock1
12.09.24Terns Pharmaceuticals director Quigley sells $172,350 in stock2
11.09.24Terns Pharmaceuticals prices $150M stock offering3
Seite:  Weiter >>
51 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1